Effect of VKORC1 –1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients
Authors:
- Kunihiko ItohKIKunihiko Itoh
- 1 June 2009
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 124 (2) , 161-166
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimenBlood, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivityHuman Molecular Genetics, 2005
- Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance doseThe Pharmacogenomics Journal, 2005
- Identification of the gene for vitamin K epoxide reductaseNature, 2004
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Biochemistry and molecular biology of the human CYP2C subfamilyPharmacogenetics, 1994
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994